Patterns of viral decline during PEG‐interferon alpha‐2b therapy in HBeAg‐positive chronic hepatitis B: Relation to treatment response
Martijn J. ter Borg, Monika van Zonneveld, Stefan Zeuzem, Hakan Senturk, Ulus S. Akarca, Christopher Simon, Bettina E. Hansen, Bart L. Haagmans, Robert A. de Man, Solko W. Schalm, Harry L.A. Janssen, HBV 99‐01 Study Group – 29 August 2006 – In chronic hepatitis B, it is difficult to predict an early therapeutic response. We investigated the viral decline during therapy with pegylated interferon alpha‐2b (PEG‐IFN) with or without lamivudine in 266 HBeAg‐positive chronic hepatitis B patients.